Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
pharmaceutical investing Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan
U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease
Prismo Metals Announces Closing of Upsized Private Placement Silver King Exploration to Begin in July
